Open an account

Trinity Biotech

TRIB · NASDAQ

$7.79−$0.40 (−4.88%)TodayMarket closed ·
Prev close $8.19

About TRIB

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Employees
401
Headquarters
DUBLIN, Wicklow
Listed
Oct 21, 1992
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
trinitybiotech.com

TRIB key statistics

Market cap
5.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
14.54K
Volume
3.96K
Open price
$8.12
High today
$8.12
Low today
$7.57
52 Week high
$52.50
52 Week low
$5.01

Trinity Biotech (TRIB) at a glance

Trinity Biotech (TRIB) last traded at $7.79, with a market cap of 5.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $7.57 and $8.12. The current price is 2.9% above the day's low and 4.1% below its high.

Volume so far is 3.96K shares, below the average of 14.54K shares a day.

Over the past year Trinity Biotech has ranged from $5.01 to $52.50, and now sits 6% of the way up that range.

Trinity Biotech met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q4 FY24 it reported -$34.20 per share against an estimate of -$9.18.

TRIB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 16.5% on average.

  1. Q3 FY22: reported -$35.25 per share against an estimate of -$6.12
  2. Q4 FY22: reported -$39.75 per share against an estimate of -$9.18
  3. Q1 FY23: reported -$22.80 per share against an estimate of -$9.18
  4. Q2 FY23: reported -$22.50 per share against an estimate of -$13.77
  5. Q1 FY24: reported -$0.37 per share against an estimate of -$0.1224
  6. Q2 FY24: reported -$21.42 per share against an estimate of -$19.89
  7. Q3 FY24: reported -$13.80 per share against an estimate of -$16.52
  8. Q4 FY24: reported -$34.20 per share against an estimate of -$9.18

TRIB news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Shivdeep Dhaliwal

    Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

  • Avi Kapoor

    Dow Gains 100 Points; US Durable Goods Orders Decline In October

  • Avi Kapoor

    US Stocks Mixed; GDP Growth Tops Expectations

  • Akanksha Bakshi

    Why Is Trinity Biotech Stock Soaring Tuesday?

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

Similar companies

Companies in the same industry as Trinity Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.